CSIMarket
 
Twist Bioscience Corporation  (NASDAQ: TWST)
Other Ticker:  
 
 
Price: $41.8800 $-2.37 -5.356%
Day's High: $44.94 Week Perf: -0.4 %
Day's Low: $ 41.25 30 Day Perf: 2.62 %
Volume (M): 810 52 Wk High: $ 60.90
Volume (M$): $ 33,935 52 Wk Avg: $44.63
Open: $44.14 52 Wk Low: $27.41



 Market Capitalization (Millions $) 2,478
 Shares Outstanding (Millions) 59
 Employees 923
 Revenues (TTM) (Millions $) 330
 Net Income (TTM) (Millions $) -197
 Cash Flow (TTM) (Millions $) -45
 Capital Exp. (TTM) (Millions $) 6

Twist Bioscience Corporation
Twist Bioscience Corporation is a synthetic biology company that specializes in producing high-quality DNA strands for a wide range of applications. Headquartered in San Francisco, California, Twist Bioscience was founded in 2013 and has grown to become a leading player in the field of synthetic biology.

One of the primary focuses of Twist Bioscience is the production of synthetic DNA strands, which it sells to customers in the pharmaceutical, academic, and industrial sectors. The company uses a proprietary process to manufacture DNA strands, which allows it to produce large quantities of high-quality, double-stranded DNA quickly and inexpensively.

In addition to its core synthetic DNA business, Twist Bioscience also offers a range of other products and services. These include custom gene synthesis, which allows customers to design and order specific DNA sequences for use in research and development; NGS (Next-Generation Sequencing), which allows researchers to analyze large quantities of genomic data quickly and accurately; and CRISPR gene editing, which employs a revolutionary method for altering DNA sequences with precision.

Twist Bioscience's technology platform is based on a proprietary silicon-based microchip that is capable of synthesizing millions of different DNA strands simultaneously. The company's expertise in DNA synthesis and gene editing has opened up a wide range of potential applications, including drug discovery, genetic engineering, and precision medicine.

Twist Bioscience is well-positioned in the emerging field of synthetic biology, a rapidly growing area of biotechnology that seeks to engineer biological systems for specific applications. The company is backed by a strong team of scientific experts and experienced business leaders, and has raised significant funding from top-tier investors, including ARCH Venture Partners, Illumina, and Fidelity Investments.

In summary, Twist Bioscience is a cutting-edge synthetic biology company that specializes in DNA synthesis and gene editing. Its proprietary technology platform and expertise in the field of synthetic biology have opened up a range of exciting potential applications, and the company is well-positioned to continue to lead in this exciting and rapidly growing field.


   Company Address: 681 Gateway Blvd South San Francisco 94080 CA
   Company Phone Number: 719-0671   Stock Exchange / Ticker: NASDAQ TWST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRSP   -4.83%    
GLUE   -22.24%    
RGEN        0.5% 
TECH   -1.59%    
A   -0.64%    
BIO   -3.6%    
• View Complete Report
   



Business Update

Pioneering Biotech Advances Twist Bioscience Showcases Growth and Innovation at the J.P. Morgan Healthcare Conference

Published Thu, Dec 19 2024 1:47 PM UTC

Twist Bioscience: Leading the Charge in Biotechnological Innovation at the Upcoming J.P. Morgan Healthcare Conference South San Francisco, CA As the landscape of the life sciences sector continues to evolve, Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in synthetic DNA technology, is set to further solidify its position at the 43rd Annual J.P. Morgan Hea...

Twist Bioscience Corporation

Twist Bioscience Corporation Reports Significant Progress Despite Industry Challenges in Latest Fiscal Results

Twist Bioscience Corporation: A Fiscal Review and Industry ContextTwist Bioscience Corporation (NASDAQ: TWST), a key player in the life sciences segment of the healthcare sector, has recently announced its financial results for the fourth quarter and full year of fiscal 2024, which ended on September 30, 2024. The results reveal both improvement and challenges as the company navigates the competitive biotechnology and pharmaceuticals landscape. Financial Performance HighlightsIn the latest fiscal period, Twist Bioscience demonstrated a notable reduction in its losses, reporting a loss per share of $-0.58. This marks an improvement compared to a loss of $-0.80 per share in the previous year's comparable period. Furthermore, the earnings per share (EPS) showed significant recovery from $-1.47 in the prior reporting period, suggesting improving operational efficiency and cost management.

Business Update

Twist Bioscience Pioneering Green Innovation in Biotechnology for a Sustainable Tomorrow,

Published Mon, Sep 9 2024 12:47 PM UTC

Embracing Sustainability in Biotechnology: Twist Bioscience s Commitment to Corporate ResponsibilityIn a landscape increasingly dominated by environmental concerns and the quest for sustainability, Twist Bioscience Corporation (NASDAQ: TWST) has made significant strides with the release of its 2024 Corporate Responsibility Report. This document sheds light on the company s ...

Business Update

Twist Bioscience Enhances High-Throughput Antibody Portfolio with CHO Express Antibodies

Published Wed, Jul 10 2024 3:47 PM UTC

Twist Bioscience Corporation, a leading provider of high-quality synthetic DNA using its innovative silicon platform, has recently expanded its high-throughput antibody portfolio. The company announced the launch of a CHO (Chinese hamster ovary) cell line for its Twist Express Antibodies, complementing its existing HEK293 expression system. This development aims to address t...

Business Update

Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A

Published Tue, Jul 9 2024 12:47 PM UTC

Advances in Synthetic Biology: Twist Bioscience s New Launches in Viral Controls and High-Throughput ScreeningTwist Bioscience Corporation (NASDAQ: TWST), a company renowned for its innovations in synthetic DNA using its proprietary silicon platform, has recently announced two significant advancements designed to meet the growing demands in viral research and high-throughpu...







Twist Bioscience's Segments
Americas    60.54 % of total Revenue
EMEA    31.91 % of total Revenue
APAC    7.55 % of total Revenue
Synthetic genes    29.85 % of total Revenue
Oligo pools    5.74 % of total Revenue
DNA libraries    3.15 % of total Revenue
Antibody discovery    6.42 % of total Revenue
NGS tools    54.83 % of total Revenue
Industrial chemicals materials    23.9 % of total Revenue
Academic research    19.78 % of total Revenue
Healthcare    55.65 % of total Revenue
Food agricultural    0.67 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com